Influenza knowledge and barriers to vaccination in immunosuppressed patients in the pediatric rheumatology clinic Authors: Julia G. Harris, Leslie Favier, Jordan T. Jones, Maria Ibarra, Michael J. Holland, Emily Fox, Kelly Jensen, Ashley K. Sherman, Ashley M. Cooper Published: 2024 ABSTRACT BackgroundMost patients with a pediatric rheumatic disease are at increased risk of influenza due to immunosuppressive medication use. Despite initial quality improvement efforts, our influenza vaccination rate plateaued at 72%, which prompted a survey of patients and families to assess provider vaccine recommendations, influenza knowledge, and barriers to influenza vaccination.MethodsPatients on immunosuppressive medication or their parent were eligible to complete a survey between July 2019 and January 2020. Survey questions assessed demographics, rheumatology diagnosis, immunosuppressive medication(s), influenza vaccination recommendation, patient/parent influenza knowledge, and barriers to influenza vaccination. Influenza vaccination rates for immunosuppressed patients were acquired each influenza season from 2015–2020 and tracked on a control chart.ResultsOf the 226 completed surveys, 145 (64.2%) were completed by parents and 81 (35.8%) by patients. The majority (85%) reported the influenza vaccine was recommended. The most common reasons for not receiving the influenza vaccine included: worry about disease flare (25.6%), concern the vaccine will cause influenza (25.6%), and lack of vaccine effectiveness (20.5%). Parents (40.9%) were more worried about disease flare compared to patients (17%; p = 0.024). Most respondents were able to correctly answer fever, cough and/or congestion as the most common symptoms of influenza; however, 23% answered gastrointestinal symptoms and 10.2% joint swelling. Most respondents (95.1%) were aware that immunosuppressive medication increases risk of infection. The average weekly influenza vaccination rate for the 2019–2020 flu season was 85.5%, which increased from 72.0% the previous year. Parents with higher education status were more likely to have their child receive the influenza vaccine compared to parents with less education.ConclusionsThis survey indicates that respondents understand the potential severity of influenza and the increased risk of infection due to immunosuppressive medication use; however, many inaccurately identified the most common symptoms of influenza and also reported misconceptions of influenza vaccine risks. The barriers identified in this survey will help drive future improvement efforts to increase influenza vaccination rates in this high-risk population. Background Most patients with a pediatric rheumatic disease are at increased risk of influenza due to immunosuppressive medication use. Immunocompromised individuals are at risk for more severe and complicated influenza infection [1, 2]. Influenza infections also lead to more hospitalizations, morbidity, and mortality in patients with systemic lupus erythematosus (SLE) due to a dysregulated immune system and medication use [3–5]. Hospitalizations due to serious infections are 12 times higher in SLE compared to non-SLE patients [5]. Moreover, adults with SLE that received an influenza vaccination had decreased hospitalizations with less admissions to the intensive care unit, decreased in-hospital dialysis, and 49% lower mortality risk [6]. Infections are also increased in patients with juvenile idiopathic arthritis (JIA) on immunosuppressive medications [7–11]. In a study of over 46,000 patients with rheumatoid arthritis, influenza incidence was increased and there was an increased rate of complications due to infection regardless of immunosuppressive medication use [12]. Infection risk and associated mortality is also increased in patients with inflammatory myopathies [13–15]. Further, reports suggest an increased risk of rheumatic disease flare with an influenza infection [16–19]. The Centers for Disease Control and Prevention (CDC) recommends annual influenza vaccination for all children six months of age and older [20]. The American College of Rheumatology guidelines for the treatment of JIA strongly recommends inactivated influenza immunization in all children with JIA [21]. The European League Against Rheumatism (EULAR) and Pediatric Rheumatology European Society’s combined pediatric vaccine guidance also strongly recommends influenza vaccination for all patients with pediatric rheumatic disease treated with glucocorticoids or disease-modifying anti-rheumatic drugs [22]. EULAR recommendations suggest that influenza vaccination be strongly considered for the majority of adult patients with autoimmune inflammatory rheumatic diseases [23]. Furthermore, the Infectious Diseases Society of America (IDSA) guidelines for vaccination of the immunocompromised host strongly recommends inactivated influenza vaccination in patients at least six months of age and older except for patients who are not likely to respond [24]. Despite strong recommendations from several national and international agencies, influenza vaccination rates are suboptimal. The general pediatric influenza vaccination rate is 45.9% [25]. In a cross-sectional study of children with high-risk medical conditions, annual influenza vaccination was 32.8% [26]. Our pediatric rheumatology clinic influenza vaccination rate for patients on immunosuppression was 64% in the 2015–2016 influenza season. Since that time, our division performed quality improvement efforts to increase our vaccination rate, and the vaccination rate in our population plateaued at 72%. This prompted our project to conduct a survey to assess influenza vaccination recommendation, patient and parent knowledge of influenza, and barriers to influenza vaccination to ultimately help identify additional impactful interventions to improve the influenza vaccination rate in our high-risk patients. Methods Study design and participants A convenience sample of patients (15 years of age and older) or parents of children (6 months of age and older) were eligible for inclusion in this project if the patient was seen in the rheumatology clinic and had a pediatric rheumatic disease on immunosuppression. Data collection Survey questions assessed patient age, pediatric rheumatic disease diagnosis, and immunosuppressive medication use. If inclusion criteria were met, then the parent or patient completed a REDCap survey, which was administered between July 2019 and January 2020. Additional questions asked parental education level, influenza vaccine recommendation, vaccination status, influenza knowledge, and barriers to influenza vaccination. For vaccination status, self-reported vaccination rate referred to the 2018–2019 influenza season. If no vaccine was received that season, a follow-up question asked for reasons why. Influenza vaccination rates of patients with a pediatric rheumatic disease on immunosuppression were acquired each influenza season via chart review from 2015–2020 and tracked on a control chart. Special cause was assessed by the presence of standard control chart rules: 1) shift – 8 or more points in a row above or below the center line and 2) trend – 6 consecutive points increasing or decreasing [27] (Fig. 1).Fig. 1Rheumatology Patients on Immunosuppression that Received Influenza Vaccination. Control chart of the vaccination rate of patients on immunosuppression seen in the rheumatology clinic. The dark blue line represents the weekly data, the purple line is the center line (mean), and the red lines indicate the upper and lower control limits Rheumatology Patients on Immunosuppression that Received Influenza Vaccination. Control chart of the vaccination rate of patients on immunosuppression seen in the rheumatology clinic. The dark blue line represents the weekly data, the purple line is the center line (mean), and the red lines indicate the upper and lower control limits Statistical analysis Logistic regression models were used to assess if patient characteristics (age, parental education, diagnosis, and medications) were linked to influenza vaccination. Fisher’s Exact tests were used to evaluate differences between patients’ and parents’ responses for why the influenza vaccine was not received. SAS version 9.4 (SAS Institute, Inc., Cary, NC) was used for all analyses. Results Of the 226 respondents that met inclusion criteria, there were 145 (64.2%) parents and 81 (35.8%) patients that completed the survey (Table 1). The patients had an average age of 11.7 years for those under 18 years of age, and 14.6% of patients were 18 years of age or older. The majority (59.3%) were diagnosed with JIA, while 8.9% had SLE, 8% had juvenile dermatomyositis, and 7.1% had localized scleroderma. Methotrexate was the most common (52.7%) immunosuppressive medication followed by tumor necrosis factor inhibitors (38.1%). The majority (82.7%, CI 77.3%−87.1%) of parents and patients reported the patient received the influenza vaccine. Patient age was not associated with receiving an influenza vaccine (p = 0.314). Parent education level was associated with their child receiving the influenza vaccine with parents with some college experience (some college, bachelor’s degree, advanced degree) being 3.8 times more likely to have their child receive the influenza vaccine compared to parents with grade school or some high school level education (OR = 3.8, 95% CI 1.74–8.21). No diagnosis or immunosuppressive medications were found to be associated with receiving the influenza vaccine. Table 1Demographics and clinical characteristics of the survey respondentsParent (number (%))Patient (number (%))Total (number (%))Odds Ratios for getting vaccine (95% Confidence Intervals)p-value¥Number of respondents145 (64.2)81 (35.8)226Patient age 2–521 (14.5)021 (9.3)3.57 (0.39–32.96)‡0.314‡ 6–944 (30.3)044 (19.5)0.80 (0.24–2.73)‡ 10–1463 (43.4)063 (27.9)1.07 (0.33–3.50)‡ 15–1715 (10.3)50 (61.7)65 (28.8)0.55 (0.18–1.65)‡ 18 or older2 (1.4)31 (38.3)33 (14.6)Parental education level Grade school25 (17.2)2 (2.5)27 (11.9)0.004§ Some high school6 (4.1)20 (24.7)26 (11.5) Completed high school/GED15 (10.3)14 (17.3)29 (12.8)1.81 (0.62–5.27)§ Some college38 (26.2)22 (27.2)60 (26.5)3.78 (1.74–8.21)§ Bachelor's degree36 (24.8)13 (16)49 (21.7) Advanced degree25 (17.2)10 (12.3)35 (15.5)Patient Diagnosisa Juvenile idiopathic arthritis93 (64.1)41 (50.6)134 (59.3)1.48 (0.74–2.97)0.265 Lupus4 (2.8)16 (19.8)20 (8.9)0.82 (0.26–2.60)0.734 Juvenile dermatomyositis14 (9.7)4 (4.9)18 (8.0)0.38 (0.13–1.08)0.068 Localized scleroderma13 (9.0)3 (3.7)16 (7.1)0.90 (0.24–3.31)0.87 Vasculitis2 (1.4)4 (4.9)6 (2.7)1.74 (0.32-inf)0.316 Other22 (15.2)14 (17.3)36 (15.9)0.84 (0.34–2.08)0.705Medicationa,b Methotrexate85 (58.6)34 (42.0)119 (52.7)1.21 (0.61–2.41)0.589 Leflunomide7 (4.8)7 (8.6)14 (6.2)0.75 (0.20–2.82)0.671 Tumor necrosis factor inhibitor56 (38.6)30 (37.0)86 (38.1)0.86 (0.43–1.74)0.674 Abatacept2 (1.4)4 (4.9)6 (2.7)0.40 (0.07–2.29)0.306 Tocilizumab5 (3.5)4 (4.9)9 (4.0)0.72 (0.14–3.60)0.688 Anakinra5 (3.5)0 (0)5 (2.2)1.42 (0.25-inf)0.384 Canakinumab1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827 Mycophenolate14 (9.7)19 (23.5)33 (14.6)1.20 (0.43–3.32)0.729 Azathioprine1 (0.7)4 (4.9)5 (2.2)1.42 (0.25-inf)0.384 Cyclophosphamide0 (0)0 (0)0 (0)N/AN/A Cyclosporine1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827 Rituximab1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827 Belimumab0 (0)0 (0)0 (0)N/AN/A Corticosteroids11 (7.6)13 (16.1)24 (10.6)1.05 (0.34–3.26)0.936 Secukinumab1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827Flu vaccine received previous flu seasonc,b Yes123 (84.8)64 (79)187 (82.7) No22 (15.2)17 (21)39 (17.3)Up to date on other vaccinesb Yes136 (93.8)73 (90.1)209 (92.5) No7 (4.8)3(3.7)10 (4.4) Not sure2 (1.4)5 (6.2)7 (3.1)Two most common symptoms of influenzaa Fever124 (85.5)62 (76.5)186 (82.3) Congestion73 (50.3)33(40.7)76 (33.6) Cough62 (42.8)34 (42)96 (42.5) Vomiting22 (15.2)25 (30.9)47 (20.8) Diarrhea6 (4.1)4 (4.9)10 (4.4) Joint swelling6 (4.1)7 (8.6)13 (10.2)Recommendations from medical providersa,b Rheumatologist127 (87.6)65 (80.2)192 (85) Primary care provider95 (65.5)36 (44.4)131 (58) Another doctor/medical provider13 (9)15 (18.5)28 (12.4) No doctor or medical provider6 (4.1)4 (4.9)10 (4.4)Did you know people can die from the flu? Yes140 (96.6)76 (93.8)216 (95.6) No5 (3.4)5 (6.2)10 (4.4)Did you know certain medications can increase the risk of developing the flu? Yes142 (97.9)73 (90.1)215 (95.1) No3 (2.1)8 (9.9)11 (4.9)‡18 or older used as reference category§Less than high school degree used as reference category¥Significance of receiving an influenza vaccineaable to select more than one optionbquestions all pertinent to patientcdefined as September 2018-April 2019 Table 1Demographics and clinical characteristics of the survey respondentsParent (number (%))Patient (number (%))Total (number (%))Odds Ratios for getting vaccine (95% Confidence Intervals)p-value¥Number of respondents145 (64.2)81 (35.8)226Patient age 2–521 (14.5)021 (9.3)3.57 (0.39–32.96)‡0.314‡ 6–944 (30.3)044 (19.5)0.80 (0.24–2.73)‡ 10–1463 (43.4)063 (27.9)1.07 (0.33–3.50)‡ 15–1715 (10.3)50 (61.7)65 (28.8)0.55 (0.18–1.65)‡ 18 or older2 (1.4)31 (38.3)33 (14.6)Parental education level Grade school25 (17.2)2 (2.5)27 (11.9)0.004§ Some high school6 (4.1)20 (24.7)26 (11.5) Completed high school/GED15 (10.3)14 (17.3)29 (12.8)1.81 (0.62–5.27)§ Some college38 (26.2)22 (27.2)60 (26.5)3.78 (1.74–8.21)§ Bachelor's degree36 (24.8)13 (16)49 (21.7) Advanced degree25 (17.2)10 (12.3)35 (15.5)Patient Diagnosisa Juvenile idiopathic arthritis93 (64.1)41 (50.6)134 (59.3)1.48 (0.74–2.97)0.265 Lupus4 (2.8)16 (19.8)20 (8.9)0.82 (0.26–2.60)0.734 Juvenile dermatomyositis14 (9.7)4 (4.9)18 (8.0)0.38 (0.13–1.08)0.068 Localized scleroderma13 (9.0)3 (3.7)16 (7.1)0.90 (0.24–3.31)0.87 Vasculitis2 (1.4)4 (4.9)6 (2.7)1.74 (0.32-inf)0.316 Other22 (15.2)14 (17.3)36 (15.9)0.84 (0.34–2.08)0.705Medicationa,b Methotrexate85 (58.6)34 (42.0)119 (52.7)1.21 (0.61–2.41)0.589 Leflunomide7 (4.8)7 (8.6)14 (6.2)0.75 (0.20–2.82)0.671 Tumor necrosis factor inhibitor56 (38.6)30 (37.0)86 (38.1)0.86 (0.43–1.74)0.674 Abatacept2 (1.4)4 (4.9)6 (2.7)0.40 (0.07–2.29)0.306 Tocilizumab5 (3.5)4 (4.9)9 (4.0)0.72 (0.14–3.60)0.688 Anakinra5 (3.5)0 (0)5 (2.2)1.42 (0.25-inf)0.384 Canakinumab1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827 Mycophenolate14 (9.7)19 (23.5)33 (14.6)1.20 (0.43–3.32)0.729 Azathioprine1 (0.7)4 (4.9)5 (2.2)1.42 (0.25-inf)0.384 Cyclophosphamide0 (0)0 (0)0 (0)N/AN/A Cyclosporine1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827 Rituximab1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827 Belimumab0 (0)0 (0)0 (0)N/AN/A Corticosteroids11 (7.6)13 (16.1)24 (10.6)1.05 (0.34–3.26)0.936 Secukinumab1 (0.7)0 (0)1 (0.4)0.21 (0.01-inf)0.827Flu vaccine received previous flu seasonc,b Yes123 (84.8)64 (79)187 (82.7) No22 (15.2)17 (21)39 (17.3)Up to date on other vaccinesb Yes136 (93.8)73 (90.1)209 (92.5) No7 (4.8)3(3.7)10 (4.4) Not sure2 (1.4)5 (6.2)7 (3.1)Two most common symptoms of influenzaa Fever124 (85.5)62 (76.5)186 (82.3) Congestion73 (50.3)33(40.7)76 (33.6) Cough62 (42.8)34 (42)96 (42.5) Vomiting22 (15.2)25 (30.9)47 (20.8) Diarrhea6 (4.1)4 (4.9)10 (4.4) Joint swelling6 (4.1)7 (8.6)13 (10.2)Recommendations from medical providersa,b Rheumatologist127 (87.6)65 (80.2)192 (85) Primary care provider95 (65.5)36 (44.4)131 (58) Another doctor/medical provider13 (9)15 (18.5)28 (12.4) No doctor or medical provider6 (4.1)4 (4.9)10 (4.4)Did you know people can die from the flu? Yes140 (96.6)76 (93.8)216 (95.6) No5 (3.4)5 (6.2)10 (4.4)Did you know certain medications can increase the risk of developing the flu? Yes142 (97.9)73 (90.1)215 (95.1) No3 (2.1)8 (9.9)11 (4.9)‡18 or older used as reference category§Less than high school degree used as reference category¥Significance of receiving an influenza vaccineaable to select more than one optionbquestions all pertinent to patientcdefined as September 2018-April 2019 Demographics and clinical characteristics of the survey respondents ‡18 or older used as reference category §Less than high school degree used as reference category ¥Significance of receiving an influenza vaccine aable to select more than one option bquestions all pertinent to patient cdefined as September 2018-April 2019 The most common reasons for not receiving the influenza vaccine (Table 2) included: worry about disease flare (25.6%), concern the vaccine will cause influenza (25.6%), presumed lack of vaccine effectiveness (20.5%), and concern the influenza vaccine makes people sick (20.5%). No one selected lack of availability, and only one parent reported lack of severity of influenza as being a reason for not receiving the influenza vaccine. One parent and one child reported pain with injection as being a reason for not getting the influenza vaccine. One parent and five patients (29.4%) stated they would have received the vaccine but forgot. Three parents (13.6%) reported not giving any vaccines to their child. Parents were more worried (40.9%) about disease flare as a reason to not receive the influenza vaccine compared to patients (17%) (p = 0.024). No other reasons were found to be statistically different between parent and patient reports. Table 2Reasons why the influenza vaccine was not receivedaParent (n = 22)number (%)Patient (n = 17)number (%)Total (n = 39)number (%)p-value1. I think the flu shot can cause the flu4 (18.2)6 (35.3)10 (25.6)0.2822. The flu shot makes you sick4 (18.2)4 (23.5)8 (20.5)0.7093. The injection is painful1 (4.5)1 (5.9)2 (5.1)1.0004. I worry the vaccine will flare/worsen my child’s/my rheumatic disease9 (40.9)1 (5.9)10 (25.6)0.0245. I do not think the vaccine will work5 (22.7)3 (17.6)8 (20.5)1.0006. My child does/I do not get the flu, so it is not worth getting the vaccine2 (9.1)1 (5.9)3 (7.7)1.0007. The flu is not that serious1 (4.5)0 (0)1 (2.6)1.0008. I would have given my child/gotten the vaccine but forgot to get it1 (4.5)5 (29.4)6 (15.4)0.0689. I would have given/gotten the flu vaccine, but the doctor’s office did not have it available0 (0)0 (0)0 (0)N/A10. I do not give any vaccinations to my child/I choose not to receive any vaccinations3 (13.6)0 (0)3 (7.7)0.24311. My parent does not believe in any vaccinationsN/A0 (0)N/AN/A12. I would have gotten the flu shot but my parent refusedN/A0 (0)N/AN/AaRespondents were able to select more than one answer Table 2Reasons why the influenza vaccine was not receivedaParent (n = 22)number (%)Patient (n = 17)number (%)Total (n = 39)number (%)p-value1. I think the flu shot can cause the flu4 (18.2)6 (35.3)10 (25.6)0.2822. The flu shot makes you sick4 (18.2)4 (23.5)8 (20.5)0.7093. The injection is painful1 (4.5)1 (5.9)2 (5.1)1.0004. I worry the vaccine will flare/worsen my child’s/my rheumatic disease9 (40.9)1 (5.9)10 (25.6)0.0245. I do not think the vaccine will work5 (22.7)3 (17.6)8 (20.5)1.0006. My child does/I do not get the flu, so it is not worth getting the vaccine2 (9.1)1 (5.9)3 (7.7)1.0007. The flu is not that serious1 (4.5)0 (0)1 (2.6)1.0008. I would have given my child/gotten the vaccine but forgot to get it1 (4.5)5 (29.4)6 (15.4)0.0689. I would have given/gotten the flu vaccine, but the doctor’s office did not have it available0 (0)0 (0)0 (0)N/A10. I do not give any vaccinations to my child/I choose not to receive any vaccinations3 (13.6)0 (0)3 (7.7)0.24311. My parent does not believe in any vaccinationsN/A0 (0)N/AN/A12. I would have gotten the flu shot but my parent refusedN/A0 (0)N/AN/AaRespondents were able to select more than one answer Reasons why the influenza vaccine was not receiveda aRespondents were able to select more than one answer Overall, 92.5% of respondents reported to be up-to-date on all other vaccines besides the influenza vaccine. When asked for the two most common symptoms of influenza, 82.3% answered fever, 76.1% answered cough and/or congestion, 23% answered gastrointestinal symptoms (vomiting and/or diarrhea) and 10.2% answered joint swelling. The majority (85%) reported receiving a recommendation to receive the influenza vaccine from their [child’s] rheumatologist, while 58% also received the recommendation from their primary care provider. Almost all the respondents (95.6%) were aware that influenza could cause death and that immunosuppressive medication increased the risk of infection (95.1%). The average weekly influenza vaccination rate increased from 72% to 85.5% indicating a special cause (Fig. 1). Discussion We successfully implemented a survey of patients with pediatric rheumatic disease on immunosuppressive therapy and their parents to assess influenza vaccination recommendation, patient/parent knowledge of influenza, and barriers to influenza vaccination. Barriers to influenza vaccination and gaps in influenza knowledge were identified in this high-risk immunosuppressed patient population. This survey, as part of a larger quality improvement project, led to an increase in the influenza vaccination rate in our patients with pediatric rheumatic disease on immunosuppressive therapy. We found that 85% of respondents in our survey had the influenza vaccine recommended by the rheumatologist and 58% by the child’s primary care physician. Only 4.4% reported no vaccine recommendation. A previous study that assessed barriers and facilitators to vaccination in adults with immune-mediated inflammatory diseases found recommendation from a trusted healthcare provider to be an important facilitator [28]. Additionally, others have found that lack of physician recommendation was the most common reason why patients with SLE did not receive influenza or pneumococcal vaccination [29]. Additional studies also report that the lack of health care provider recommendation is a major barrier to getting the influenza vaccine, and/or a health care provider recommendation was a significant influencer to getting a vaccine in both patients with and without rheumatic diseases [3, 30–33]. We found two of the top reasons for not getting a vaccination as worry the influenza vaccine can cause influenza and that the influenza vaccine makes you sick. However, no survey respondents listed availability as a barrier. Our survey also identified that 25.6% of respondents believe that the vaccine could trigger a flare of their disease, with much higher percent of parents (40.9%) reporting this versus patients (5.9%). Additionally, 20.5% of respondents stated lack of efficacy as a reason for not getting the influenza vaccine. A previous study showed that a facilitator of getting vaccinated was higher perceived infection risk [28]. A survey of patients with SLE from China also identified worry about SLE exacerbation as one of the three biggest reasons for non-vaccination [34]. Additional published barriers to vaccination include concern about adverse events, lack of presumed efficacy of the vaccine, and lack of awareness of vaccine availability [3, 32–37]. Our study found that the majority (95.1%) of respondents knew that their immunosuppressive medication could increase the risk of developing influenza. Influenza causes a respiratory infection with classic symptoms of fever, cough, myalgias, chills, sweats, and fatigue [38]. When assessing knowledge of common influenza symptoms, cough and congestion collectively and fever were picked by a majority of respondents. However, gastrointestinal symptoms (vomiting and/or diarrhea) were picked by 25.2% of respondents despite these symptoms occurring in 10% or less of children with influenza [39]. Around 10% of our respondents listed joint swelling as one of the two most common symptoms of influenza despite joint swelling not being a common sign at time of influenza diagnosis in children [39]. Another study noted 64.5% of patients visiting a primary health care center had good knowledge of seasonal flu and 73.3% had good knowledge of the influenza vaccine [40]. Through a separate quality improvement initiative involving physician and nurse education, patient education handouts, posting signs in clinic, and more, we saw an improvement in our vaccination rate of patients on immunosuppression from 63.8% to 72% from 2015 to 2019. We saw additional improvement in our vaccination rate in tandem with this survey using quality improvement methodology to 85.5%. Studies note 25.3% to 62.6% of patients with inflammatory arthritis, SLE, and/or other inflammatory rheumatic disease being vaccinated against influenza [3, 33, 41–45]. Mina, et al. reported influenza vaccination prescribing rates in seven pediatric rheumatology centers in the United States, Brazil, and India and found that benchmarking of this quality indictor for childhood-onset SLE is quite variable from 0 to 100% [46]. Harris, et al. noted that the influenza vaccine was given to patients with childhood-onset SLE in 75.8% of patient-years [47]. Furthermore, an additional study found 24.2% of children with pediatric inflammatory rheumatic diseases on immunosuppression received an influenza vaccine [48]. There are many strengths of our study. First, while there are several reports on influenza vaccination barriers in adults with inflammatory rheumatic diseases, there is a paucity of studies specific to the pediatric rheumatic population. Furthermore, our study allowed for both patient and parent input. Our results confirm that barriers differ between patient and parent respondents, specifically worry about disease flare. This knowledge could lead to tailored family education in the future. The link of influenza vaccination to parental education level also is valuable information and should lead to an emphasis on health literacy. Additionally, our study was able to assess for a broad variety of barrier domains including logistical, educational, perceptions and ideological differences. There are several limitations with our study. Due to a high self-reported and parent-reported influenza vaccination rate, our denominator for respondents on the reasons for why influenza vaccine not received is somewhat low. We also acknowledge that the reasons for not receiving a vaccine in our survey was not an exhaustive list. For example, we did not assess for subjective norm, past influenza vaccination behavior, past infection with influenza, and general attitude towards the vaccine, which were all highlighted in a review on barriers of influenza vaccination [49]. An additional limitation is that our survey only assessed reasons that patients did not receive the influenza vaccination and not reasons patients did receive the vaccine. This is important as one study on adults with inflammatory rheumatic diseases concluded that facilitators towards vaccination were more important than barriers [50]. As with many improvement projects, we cannot definitively state what led to improvements in our influenza vaccination rate the year of our survey. However, we presume that it was at least in part due to continued engagement from physicians and nurses in this project, which led to more discussion with patients and families regarding recommendation of the vaccine. Conclusions Our survey identified several barriers to receiving the influenza vaccine in our patients with rheumatic diseases on immunosuppression. The most common barriers included concern for the vaccine causing influenza, worry about risk of disease flare, vaccine side effects, and lack of vaccine efficacy. Influenza knowledge is also lacking. By establishing the salient barriers to influenza vaccination in this high-risk pediatric population, we are better able to inform improvement initiatives that will educate patients and families and improve outcomes.